Global Viral Vector Manufacturing CDMO Services Market Growth (Status and Outlook) 2024-2030

The global Viral Vector Manufacturing CDMO Services market size is predicted to grow from US$ 5458 million in 2024 to US$ 9420 million in 2030; it is expected to grow at a CAGR of 9.5% from 2024 to 2030.

Viral Vector Manufacturing CDMO services refer to providing professional viral vector production and development services to biopharmaceutical companies. These viral vectors are usually used in gene therapy, vaccine development, cell therapy and other fields. CDMO organizations are responsible for the design and optimization of viral vectors to large-scale production in accordance with GMP standards, ensuring the safety and effectiveness of the products, while strictly controlling the quality of each production link. These services provide key technical support for biopharmaceutical companies to help accelerate the development and commercialization of their products.

United States market for Viral Vector Manufacturing CDMO Services is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Viral Vector Manufacturing CDMO Services is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Viral Vector Manufacturing CDMO Services is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Viral Vector Manufacturing CDMO Services players cover Thermo Fisher Scientific Inc., Revvity, Charles River Laboratories, AGC Inc. Group (AGC Biologics), NorthX Biologics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

LPI (LP Information)' newest research report, the “Viral Vector Manufacturing CDMO Services Industry Forecast” looks at past sales and reviews total world Viral Vector Manufacturing CDMO Services sales in 2023, providing a comprehensive analysis by region and market sector of projected Viral Vector Manufacturing CDMO Services sales for 2024 through 2030. With Viral Vector Manufacturing CDMO Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vector Manufacturing CDMO Services industry.

This Insight Report provides a comprehensive analysis of the global Viral Vector Manufacturing CDMO Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Viral Vector Manufacturing CDMO Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Viral Vector Manufacturing CDMO Services market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vector Manufacturing CDMO Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vector Manufacturing CDMO Services.

This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vector Manufacturing CDMO Services market by product type, application, key players and key regions and countries.

Segmentation by Type:
Adeno-associated Virus
Lentivirus
Retrovirus
Adenovirus
Other

Segmentation by Application:
Gene Therapy
Vaccine Development
Cell Therapy

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific Inc.
Revvity
Charles River Laboratories
AGC Inc. Group (AGC Biologics)
NorthX Biologics
Lonza
Avid Bioservices, Inc.
Exothera
Merck KGaA
Batavia Biosciences
SK pharmteco Inc.
Biovian
Curia Vector Technology
Esco Aster
ABL, Inc.
Genezen
Pharmaron
Roche AG
FinVector
FUJIFILM Diosynth Biotechnologies
Kaneka Eurogentec S.A. (Kaneka Corporation)
Oxford Biomedica plc
Sanofi S.A.

Please note: The report will take approximately 2 business days to prepare and deliver.